Literature DB >> 29687055

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade.

Sakeena Fatima1, Jesse Veenstra2, Albert S Antonyan2, Laurie Kohen2.   

Abstract

Entities:  

Keywords:  PD-L1, programmed cell death ligand 1; TGF-β, transforming growth factor-β; chemotherapy rash; immune checkpoint inhibitor; programmed cell death ligand 1; transforming growth factor-β

Year:  2018        PMID： 29687055      PMCID： PMC5909478          DOI： 10.1016/j.jdcr.2017.10.004

Source DB:  PubMed          Journal:  JAAD Case Rep        ISSN： 2352-5126


× No keyword cloud information.
  6 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

2.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

Authors:  Veronica J Shi; Nemanja Rodic; Scott Gettinger; Jonathan S Leventhal; Julia P Neckman; Michael Girardi; Marcus Bosenberg; Jennifer N Choi
Journal:  JAMA Dermatol       Date:  2016-10-01       Impact factor: 10.282

3.  Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.

Authors:  Julius Strauss; Christopher R Heery; Jeffrey Schlom; Ravi A Madan; Liang Cao; Zhigang Kang; Elizabeth Lamping; Jennifer L Marté; Renee N Donahue; Italia Grenga; Lisa Cordes; Olaf Christensen; Lisa Mahnke; Christoph Helwig; James L Gulley
Journal:  Clin Cancer Res       Date:  2018-01-03       Impact factor: 12.531

4.  Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.

Authors:  Simone M Goldinger; Pascale Stieger; Barbara Meier; Sara Micaletto; Emmanuel Contassot; Lars E French; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

Review 5.  Complexities of TGF-β targeted cancer therapy.

Authors:  Erin C Connolly; Julia Freimuth; Rosemary J Akhurst
Journal:  Int J Biol Sci       Date:  2012-07-12       Impact factor: 6.580

6.  Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding.

Authors:  Emily S Yin; Mariam B Totonchy; Jonathan S Leventhal
Journal:  JAAD Case Rep       Date:  2017-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.